BRPI0412607A - método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes - Google Patents

método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes

Info

Publication number
BRPI0412607A
BRPI0412607A BRPI0412607-6A BRPI0412607A BRPI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A
Authority
BR
Brazil
Prior art keywords
protein variant
efficacy
enhancing
biological reaction
modifying proteins
Prior art date
Application number
BRPI0412607-6A
Other languages
English (en)
Inventor
Yong-Hoon Chung
Hak-Sup Lee
Ki-Wan Yi
Youn-Hwa Heo
Jae-Youn Kim
Original Assignee
Medexgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Co Ltd filed Critical Medexgen Co Ltd
Publication of BRPI0412607A publication Critical patent/BRPI0412607A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

MéTODO PARA APRIMORAR A EFICáCIA DE PROTEINAS MODIFICANTES DE REAçãO BIOLóGICA E MUTEìNAS RESULTANTES A presente patente de invenção descreve uma variante de proteína que substitui resíduo de fenilalanina por valina em um meio de ligação possuindo função modificadora de reação biológica pela ligação a um receptor, agente de ligação ou substrato. Também, a presente invenção descreve um DNA que codifica uma variante de protéina, um vetor de expressão recombinante no qual o DNA é operacionalmente ligado, uma célula hospedeira transformada ou transfectada com o vetor de expressão recombinante, e um método para o preparo da variante de proteína compreendendo o cultivo da célula hospedeira e o isoladamente da variante de protéina da cultura resultante. Ademais, a presente invenção descreve uma composição farmacêuticamente possuindo a variante de protéina e uma enzima farmacologicamente aceitável.
BRPI0412607-6A 2003-07-26 2004-05-27 método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes BRPI0412607A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030051846A KR100632985B1 (ko) 2003-07-26 2003-07-26 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
PCT/KR2004/001246 WO2005010043A1 (en) 2003-07-26 2004-05-27 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins

Publications (1)

Publication Number Publication Date
BRPI0412607A true BRPI0412607A (pt) 2007-07-03

Family

ID=36284112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412607-6A BRPI0412607A (pt) 2003-07-26 2004-05-27 método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes

Country Status (14)

Country Link
US (3) US7569361B2 (pt)
EP (1) EP1668030B1 (pt)
JP (1) JP4747238B2 (pt)
KR (1) KR100632985B1 (pt)
CN (2) CN102286090A (pt)
AT (1) ATE500266T1 (pt)
AU (1) AU2004259314B2 (pt)
BR (1) BRPI0412607A (pt)
CA (1) CA2528458A1 (pt)
DE (1) DE602004031642D1 (pt)
ES (1) ES2362453T3 (pt)
RU (1) RU2432360C2 (pt)
WO (1) WO2005010043A1 (pt)
ZA (1) ZA200600502B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
US10052343B1 (en) * 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CN119768414A (zh) * 2022-11-10 2025-04-04 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
AU3538799A (en) * 1998-04-30 1999-11-23 Kirin Brewery Company, Limited Human thrombopoietin mutants
DE60332556D1 (de) * 2002-05-01 2010-06-24 Danisco Us Inc Cytokine und cytokinrezeptoren mit reduzierter immunogenität

Also Published As

Publication number Publication date
KR100632985B1 (ko) 2006-10-11
EP1668030B1 (en) 2011-03-02
RU2006102846A (ru) 2007-09-10
JP4747238B2 (ja) 2011-08-17
EP1668030A4 (en) 2006-06-14
CN102286090A (zh) 2011-12-21
US20060008872A1 (en) 2006-01-12
CN101384620B (zh) 2011-08-17
US7569361B2 (en) 2009-08-04
ATE500266T1 (de) 2011-03-15
CN101384620A (zh) 2009-03-11
US20130089513A1 (en) 2013-04-11
KR20050013024A (ko) 2005-02-02
CA2528458A1 (en) 2005-02-03
AU2004259314B2 (en) 2006-12-07
JP2007524403A (ja) 2007-08-30
RU2432360C2 (ru) 2011-10-27
US20100041586A1 (en) 2010-02-18
DE602004031642D1 (de) 2011-04-14
WO2005010043A1 (en) 2005-02-03
ES2362453T3 (es) 2011-07-05
EP1668030A1 (en) 2006-06-14
AU2004259314A1 (en) 2005-02-03
ZA200600502B (en) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
Aguilar et al. β-Amino acid-containing hybrid peptides—new opportunities in peptidomimetics
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
WO2007019545A3 (en) Tissue protective peptides and uses thereof
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
Białkowska et al. Extremophilic proteases as novel and efficient tools in short peptide synthesis
PT973794E (pt) Receptores de netrina
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
Chingle et al. Azopeptides: Synthesis and pericyclic chemistry
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2005023981A3 (en) Libraries of chimeric cellulose binding proteins and methods of use thereof
WO2003082897A3 (en) Synthetic active peptide fragments
DE60032161D1 (de) P-glycoproteine und ihre verwendungen
Antonyan et al. Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV
EP1578953A4 (en) METHOD FOR DETERMINING THE PRIMARY STRUCTURE OF THE RNA MESSENGER ENCODING ENDOOLIGOPEPTIDASE A (HEOPA) ¬AF217798 | ... RECOMBINANT HUMAN
WO2002074048A3 (en) P-glycoproteins and uses thereof
IL151211A0 (en) Compositions useful for regulating parkin gene activity
JP2007529475A (ja) 等比体積の形態変換
Pfeffer-Hennig et al. Three dimensional structure of the antibiotic bacitracin A complexed to two different subtilisin proteases: Novel mode of enzyme inhibition
WO2003102209A3 (en) Alternatively spliced isoforms of human hmg co-a reductase
WO2005003289A3 (en) Ap1 amine oxidase variants

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO 20110023284 DE 11/03/2011 COM BASE NO DISPOSTO NO ART 219, INCISO "I" DA LPI E NOS ARTIGOS 10 AO 14 DA RESOLUCAO INPI/DIRPA NO 124/2006 EM VIRTUDE DE TER SIDO APRESENTADA APOS O PRAZO LEGAL DE 03 (TRES) MESES, TENDO COMO INICIO PARA A CONTAGEM DO PRAZO O DESPACHO 8.6 PUBLICADO NA RPI 2082 DE 30/11/2010.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2082 DE 30/11/2010 E CONSIDERANDO A MANIFESTACAO INTEMPESTIVA REFERENTE A PUBLICACAO SUPRA, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.